Small molecule · developed by United Therapeutics
Ralinepag (APD811) is a drug studied in pulmonary arterial hypertension, a condition of high blood pressure in the arteries of the lungs.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT03683186 | Phase 3 | PAH | Enrolling by invitation | UTHR |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Cardiovascular DiseasesConnective Tissue DiseasesFamilial Primary Pulmonary HypertensionHypertensionHypertension, PulmonaryLung DiseasesPAHPulmonary Arterial HypertensionPulmonary HypertensionRespiratory Tract DiseaseVascular Diseases
See UTHR's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
UTHR catalysts and pipeline →